Insulin inhalation - Alkermes/Eli Lilly

Drug Profile

Insulin inhalation - Alkermes/Eli Lilly

Alternative Names: AIR® insulin

Latest Information Update: 11 Mar 2008

Price : $50

At a glance

  • Originator Alkermes
  • Developer Alkermes; Eli Lilly
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 07 Mar 2008 Eli Lilly terminates the development and license agreement with Alkermes for the AIR® Inhaled Insulin programme
  • 07 Mar 2008 Discontinued - Phase-III for Type-1 diabetes mellitus in World (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top